Knight Therapeutics (TSE:GUD) Shares Down 0.2% - What's Next?

Knight Therapeutics Inc. (TSE:GUD - Get Free Report) dropped 0.2% during trading on Monday . The stock traded as low as C$5.65 and last traded at C$5.70. Approximately 36,840 shares were traded during trading, a decline of 37% from the average daily volume of 58,048 shares. The stock had previously closed at C$5.71.

Wall Street Analysts Forecast Growth

Separately, Raymond James upgraded shares of Knight Therapeutics to a "moderate buy" rating in a research note on Friday, November 15th.

Knight Therapeutics Trading Down 0.2 %

The firm has a market cap of C$576.90 million, a PE ratio of -28.50, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.50. The company has a 50-day simple moving average of C$5.34 and a 200 day simple moving average of C$5.56. The company has a current ratio of 3.41, a quick ratio of 1.79 and a debt-to-equity ratio of 7.62.

Insider Buying and Selling

In related news, Director Samira Sakhia bought 20,000 shares of the business's stock in a transaction dated Monday, November 11th. The stock was acquired at an average price of C$5.15 per share, with a total value of C$103,000.00. Also, insider Sime Armoyan acquired 90,300 shares of the business's stock in a transaction on Tuesday, November 12th. The shares were purchased at an average price of C$5.13 per share, with a total value of C$463,672.44. 45.62% of the stock is currently owned by insiders.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.